Currently, there is no definitive imaging technique in the restaging of prostate carcinoma. The long term goal of this research is to determine if PET imaging with the synthetic L-leucine analog positron emission tomography (PET) radiotracer antf-[18F]FACBC will lead to improved patient care in the diagnosis and staging of prostate cancer and to elucidate the mechanism of its uptake within malignant cells. The specific hypothesis behind the proposed research is that anft-[18F]FACBC PET-CT will detect more local and extraprostatic recurrence than standard conventional imaging, especially compared with 111lndium- capromab-pendetide. This hypothesis is based in part on in-vitro and in-vivo studies demonstrating excellent uptake within human DU145 prostate cancer cell lines and within orthotopic implanted prostate tumor in nude rats, evidence of """"""""L"""""""" type transport (LAT), low accumulation in inflammatory cells, and work in humans demonstrating excellent visualization of primary and metastatic disease. The experimental focus of this proposal is on the ability of anf/-[18F]FACBC to detect recurrent prostate carcinoma and to discriminate prostatic from extra-prostatic recurrence.
The specific aims of the proposal are:
Aim 1. Investigate the ability of anfr-[18F]FACBC PET-CT imaging to detect local recurrence of prostate cancer.
Aim 2. Investigate the ability of anft-[18F]FACBC PET-CT imaging to detect extra-prostatic recurrence of prostate cancer.
Aim 3. Compare the ability of antt-[18F]FACBC PET-CT imaging to that of conventional imaging in the discrimination of local recurrence of prostate carcinoma from that of extra-prostatic recurrence. We will undertake a clinical trial with 160 patients who have undergone definitive therapy for prostate carcinoma and who have suspected recurrence based on elevated PSA. We will compare the ability of anf/-[18F]FACBC PET-CT imaging to conventional imaging especially 111lndium-capromab-pendetide in the detection of recurrence of carcinoma both locally and distantly. In addition we plan to develop pilot data (Sub-aim 1) investigating via RT-PCR analysis which LAT gene subtypes are present in an#-[18F]FACBC avid prostate tissue. We will then utilize publicly available microarray datasets to determine which signaling pathway controls the expression of the expressed LAT subtype in tumors (Sub-aim 2). We believe PET-CT imaging with antf-[18F]FACBC has the potential to serve as an important non-invasive imaging technique in the staging and restaging of prostate carcinoma and possibly to monitor therapy. Accomplishing the specific aims in this proposal will enable us to assess these possibilities by determining if anf/-[18F]FACBC is effective in the evaluation of locally recurrent disease (Specific Aim #1) and extraprostatic disease (Specific Aim #2), discriminate between prostatic versus extraprostatic recurrence (Specific Aim #3), and determine which LAT transporter (Sub-aim #1) and signaling pathway (Sub-aim #2) are responsible for anft'-[18F]FACBC uptake.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA129356-05
Application #
8111140
Study Section
Medical Imaging Study Section (MEDI)
Program Officer
Tandon, Pushpa
Project Start
2007-09-21
Project End
2013-07-31
Budget Start
2011-08-01
Budget End
2013-07-31
Support Year
5
Fiscal Year
2011
Total Cost
$234,999
Indirect Cost
Name
Emory University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Bach-Gansmo, Tore; Nanni, Cristina; Nieh, Peter T et al. (2017) Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine ((18)F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer. J Urol 197:676-683
Schuster, David M; Nanni, Cristina; Fanti, Stefano (2016) PET Tracers Beyond FDG in Prostate Cancer. Semin Nucl Med 46:507-521
Odewole, Oluwaseun A; Tade, Funmilayo I; Nieh, Peter T et al. (2016) Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT. Eur J Nucl Med Mol Imaging 43:1773-83
Odewole, Oluwaseun A; Oyenuga, Oyeladun A; Tade, Funmilayo et al. (2015) Reproducibility and reliability of anti-3-[ยน?F]FACBC uptake measurements in background structures and malignant lesions on follow-up PET-CT in prostate carcinoma: an exploratory analysis. Mol Imaging Biol 17:277-83
Okudaira, Hiroyuki; Oka, Shuntaro; Ono, Masahiro et al. (2014) Accumulation of trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in prostate cancer due to androgen-induced expression of amino acid transporters. Mol Imaging Biol 16:756-64
Schuster, David M; Nanni, Cristina; Fanti, Stefano et al. (2014) Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease. J Nucl Med 55:1986-92
Schuster, David M; Nieh, Peter T; Jani, Ashesh B et al. (2014) Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial. J Urol 191:1446-53
Amzat, Rianot; Taleghani, Pooneh; Savir-Baruch, Bital et al. (2011) Unusual presentations of metastatic prostate carcinoma as detected by anti-3 F-18 FACBC PET/CT. Clin Nucl Med 36:800-2
Savir-Baruch, Bital; Schuster, David M; Jarkas, Nashwa et al. (2011) Pilot evaluation of anti-1-amino-2-[18F] fluorocyclopentane-1-carboxylic acid (anti-2-[18F] FACPC) PET-CT in recurrent prostate carcinoma. Mol Imaging Biol 13:1272-7
Schuster, David M; Savir-Baruch, Bital; Nieh, Peter T et al. (2011) Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT. Radiology 259:852-61